India approves emergency use of remdesivir to treat COVID-19 patients

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

BENGALURU (Reuters) – India’s government said on Tuesday it has approved Gilead Sciences Inc’s antiviral drug remdesivir for emergency use in treating COVID-19 patients.

Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials. It was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators.

“(Remdesivir) approved on June 1 under emergency use with condition for five dose administration,” the Drugs Controller General of India said in an email statement.

The drugmaker did not immediately respond to an email seeking further details.

As of Tuesday, India has 198,706 cases of coronavirus and has recorded 5,598 deaths, health ministry data showed https://www.mohfw.gov.in.

Gilead Sciences had on Monday reported that remdesivir showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.

European and South Korean authorities are also looking at remdesivir, with South Korean health authorities last Friday saying they would request imports of the drug. Gilead is yet to gain regulatory approval in either market.

Reporting by Anuron Kumar Mitra and Manas Mishra in Bengaluru; Editing by Arun Koyyur

View original article here Source

Recommended For You

About the Author: GetFit